The “rules” of intermittent fasting are pretty strict: “Classically, intermittent fasting means you consume only water during ...

The average participant getting a 12-mg weekly injection lost 71 pounds in 68 weeks.  "This is beyond what we see with any ...

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

Obesity is not a single disease. New research shows distinct biological phenotypes that explain why weight gain and treatment ...

A 6-month fully remote weight-loss program tailored to veterans with serious mental illness yielded numerically greater ...

The implications from the design of the clinical GLP-1 agonist trials and studies of caloric restriction are that exercise is ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Weight-loss drug customers were caught up in telehealth scam. Here’s how to avoid being a victim - Federal Trade Commission ...

GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...